2024-516385-10-00招募中2 期
A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
Melinta Therapeutics LLC24 个研究点 分布在 8 个国家目标入组 190 人开始时间: 2024年11月26日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 190
- 试验地点
- 24
- 主要终点
- Safety assessment of ORBACTIV and KIMYRSA in pediatric populations
研究概览
简要总结
To evaluate the safety and tolerability of single-dose IV oritavancin (ORBACTIV and KIMYRSA) in pediatric subjects with Acute ABSSSI
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all the following criteria to be eligible for the study:
- •Male or female 3 months to <12 years of age at randomization
- •Diagnosis of at least one of the following ABSSSI infections (known or suspected to be caused by a gram-positive pathogen): a. Wound infection: that is either traumatic or surgical in origin, defined as an infection characterized by purulent drainage from a wound with surrounding erythema, edema, and/or induration b. Cellulitis/erysipelas: a diffuse skin infection characterized by spreading areas of erythema, edema, and/or induration c. Major cutaneous abscess: an infection characterized by a collection of pus within the dermis or subcutaneous tissue that is accompanied by surrounding erythema, edema, and/or induration
- •ABSSSI must present with at least two of the following signs and symptoms: a. Purulent drainage or discharge b. Erythema (>1 cm beyond edge of wound or abscess) c. Fluctuance d. Heat or localized warmth e. Edema/induration f. Pain or tenderness to palpation AND at least one of the following signs of systemic inflammation: a. Proximal lymph node swelling and tenderness b. Increased temperature (>38.0°C [>100.4°F]) c. Decreased temperature (<36.0°C [<96.8°F]) d. Decreased white blood cell (WBC) count (<4000/mm3) or increased WBC count (>12,000mm3) e. Bandemia >10% f. C-reactive protein (CRP) >upper limit of normal (ULN)
- •Written informed consent obtained from parent(s) or legal guardian(s), with written or documented verbal assent of the child obtained, when appropriate, before initiation of any assessments conducted solely for study purposes
排除标准
- •Subjects who meet any of the following exclusion criteria at screening will not be enrolled in the study:
- •Subjects who have received more than 72 hours of effective antibacterial drug therapy for treatment of the current episode of ABSSSI
- •Subjects who have received a glycopeptide antibiotic (e.g., vancomycin, telavancin, teicoplanin) within 24 hours of randomization
- •Subjects who have received dalbavancin within 45 days prior to randomization
- •Subjects who have been treated with oritavancin within the last 50 days
- •Subjects with infection suspected to be associated with a device or implant
- •Subjects with septic shock or hemodynamic instability
- •Subjects with ABSSSI due to, or associated with any of the following: a. Infection suspected or documented to be caused solely by gramnegative pathogens (e.g., human or animal bite, injury contaminated with fresh or saltwater, external malignant otitis), fungi, or viruses b. Wound infection (surgical or traumatic) or abscess with only gram-negative pathogens c. Concomitant infection at another site, not including a secondary ABSSSI lesion (e.g., septic arthritis, endocarditis, osteomyelitis). d. Infected burn e. Primary infection superimposed on a pre-existing skin disease with associated inflammatory changes, e.g., atopic dermatitis, eczema f. Any evolving necrotizing process (e.g., necrotizing fasciitis), gangrene, or infection suspected or proven to be caused by clostridioides species (e.g., crepitance on examination of the ABSSSI site and/or surrounding tissue(s), radiographic evidence of subcutaneous gas in proximity to the infection) g. Clinically significant viral infection (e.g., influenza, COVID-19) which, in the Investigator’s judgement, will impact the study clinical outcome assessments (e.g., subject is febrile due to the viral infection)
- •Subjects currently receiving chronic systemic immunosuppressive therapy
- •Subjects with neutropenia, defined as ab-solute neutrophil count (ANC) <500 cells/mm3
- •Subjects with severe renal impairment as an eGFR < 30 ml/min/1.73m2 when using the updated bedside Schwartz formula. For subjects under 1 year of age, severe renal impairment is defined as serum creatinine ≥ 2 times the 97.5th percentile creatinine for age, converted to mg/dL, from Table 10 OR requirement for dialysis. If you have a subject under 1 year of age with renal impairment, please consult with the Medical Monitor before enrollment (see Appendix 3).
- •Menstruating females with a positive result for the urine or serum human chorionic gonadotropin (HCG) test administered at screening
- •Females of childbearing potential (and males with female partners of childbearing potential) unwilling to practice abstinence or use at least two methods of contraception (e.g., oral contraceptives, barrier methods, approved contraceptive implants) during the entire study period
- •Subjects with a history of infusion-related immunoglobulin E (IgE)- mediated allergic reaction or hypersensitivity reaction to glycopeptides (e.g., vancomycin, telavancin, dalbavancin, oritavancin, teicoplanin) or any of their excipients
- •Subjects who are taking heparin (other than heparin flush for line patency) or warfarin, and/or require anticoagulant monitoring [activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR)]
- •Subjects receiving treatment with investigational medicinal product or investigational device within 3 months before enrollment or during the study
- •Subjects whom the investigator considers unlikely to adhere to the protocol, comply with Study Drug administration, or complete the clinical study (e.g., unlikely to survive 28 days from initiation of Study Drug)
- •Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x ULN or total bilirubin ≥2x ULN.
- •Subjects who are taking heparin (other than heparin flush for line patency) or warfarin, and/or require anticoagulant monitoring [activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR)]
- •Subjects receiving treatment with investigational medicinal product or investigational device within 3 months before enrollment or during the study
- •Subjects whom the investigator considers unlikely to adhere to the protocol, comply with Study Drug administration, or complete the clinical study (e.g., unlikely to survive 28 days from initiation of Study Drug)
- •Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x ULN or total bilirubin ≥2x ULN.
结局指标
主要结局
Safety assessment of ORBACTIV and KIMYRSA in pediatric populations
Safety assessment of ORBACTIV and KIMYRSA in pediatric populations
次要结局
- All-cause mortality assessed at the Time of Cure (ToC) visit
研究者
Michael Paul
Scientific
Melinta Therapeutics LLC
研究点 (24)
Loading locations...
相似试验
招募中
1 期
Evaluation of the Pharmacokinetics and Safety of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)2023-505060-11-00AbbVie Deutschland GmbH & Co. KG104
进行中（未招募）
1/2 期
A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in patients withnewly diagnosed Acute Myeloid Leukemia (AML) and who have mutations in enzymes isocitrate dehydrogenase 1 or 2 (IDH 1 or IDH2) and are not candidates to receive intensive induction chemotherapy.2024-511722-31-00Celgene Corp.70
招募中
3 期
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapyAcute myeloid leukemia2025-522979-29-00Fundacion PETHEMA350
招募中
3 期
A study to learn if rozanolixizumab is safe, how it moves through the body, and if it works in children with myasthenia gravisGeneralized Myasthenia Gravis2022-502074-16-00UCB Biopharma7
招募中
2 期
Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia2022-502499-22-00Celgene Corp.57